Results The drug substance used in this clinical trial was HBsAg expressed in tubers of the potato variety FL-1607. The line of potato selected for this study is designated FL-1607 HB114-16, and the antigen content was 8.5 ± 2.1 μg of HBsAg per g of transgenic potato, as detected by AUSZYME monoclonal ELISA (Abbott). The physical form of the potato-derived antigen was characterized ( 15). The HBsAg extracted from transgenic tubers cosedimented with yeast-derived HBsAg in ratezonal sucrose gradients; however, electron microscopy showed accumulation of long tubules in endoplasmic reticulum-derived vesicles. The electrophoretic mobility on Western blots indicated that the potato-expressed HBsAg was similar to yeast-derived antigen but differed in the occurrence of a doublet monomer, suggesting partial glycosylation ( 15). The tissue from the untransformed potato tubers did not express any proteins that were reactive with antibodies to HBsAg. Before entry into the trial, 168 previously vaccinated healthy adult health care workers were screened by a quantitative AUSAB assay (Abbott) for their current anti-HBs titers. Only those volunteers who had antibody titers of ≤115 mIU/ml qualified for inclusion in the study. Forty-two adult health care workers 25–58 years of age were enrolled in the study. There were 30 females and 12 males; 37 were Caucasian, 3 were African American, and two were other race. All volunteers were in excellent physical health, verified by medical history and a battery of blood tests (renal, hepatic, and hematologic) before entry into the study at day 0 and at three additional time points (days 14, 28, and 42) during the study. Study subjects were randomized into three groups and completed self-assessment diaries. The volunteers in the three groups received either 100–110 g of placebo potatoes on days 0, 14, and 28 (group one), HBsAg-transgenic potatoes on days 0 and 28 and placebo potatoes on day 14 (group two), or HBsAg-transgenic potatoes on days 0, 14, and 28 (group three). The entries of the diary cards from the study subjects were analyzed on each of three occasions in categories of abdominal pain, bowel movement related, nausea, muscle pain, fatigue, headache, and other symptoms. Comparison of the adverse effects between the group of volunteers that ingested the placebo vaccine and each of the experimental groups did not show any statistical significance when using the Kruskal–Wallis test ( 16). Blood was collected from each study volunteer on days 0, 7, 14, 21, 28, 35, 42, 56, and 70 for measurement of serum anti-HBs using the AUSAB kit with a set of standards (AUSAB quantitation panel) that enables the OD values to be expressed as mIU/ml of serum. None of the nine volunteers who had ingested three doses of nontransgenic potatoes had any significant changes in their anti-HBs titers during the study ( Fig. 1A). In contrast, 10 of 16 volunteers (63%) who ate three doses of HBsAg-containing transgenic potatoes (on days 0, 14, and 28) showed marked increases in antibody titers compared to their own day-0 titers ( P < 0.01) ( Fig. 1B). Among these individuals, six showed at least a doubling of their anti-HBs titers ( P < 0.01) after consuming one dose of transgenic potato, and four of the six showed a ≥4-fold increase ( P < 0.01) after one dose ( Table 1). The statistical significance was tested by using Fisher's exact test ( 17). All responders showed gradual increases in titers, with apparent boosting effects of the second and third doses. Four volunteers in the three-dose group achieved final titers of >1,000 mIU/ml ( Fig. 1B), with the highest at 4,785 mIU/ml. Nine of the 17 volunteers who received transgenic potatoes only twice (days 0 and 28) also showed increases in anti-HBs titers ( P < 0.01) ( Fig. 1C). Of these volunteers, five of the nine showed at least a doubling ( P < 0.05) after one dose, and two showed a ≥4-fold response after the first dose ( Table 2). The highest titer obtained in the two-dose group was 863 mIU/ml ( Fig. 1C). | Fig. 1.Time courses for changes in serum anti-HBs IgG in individual subjects. (A) Nine volunteers in group one consumed placebo potatoes on days 0, 14, and 28 (open arrowheads). None of the volunteers had any significant changes in their anti-HBs-specific titers (more ...) |
| Table 1. Increase in anti-HBs antibody titer in 9 of 17 volunteers who ate three doses of HBsAg-transgenic potatoes |
| Table 2. Increase in anti-HBs antibody titer in 10 of 16 volunteers who ate two doses of HBsAg-transgenic potatoes |
Statistical methods were used to contrast the antibody responses of the three groups, involving all volunteers who completed the trial. Responses of controls (group one) were contrasted versus those who received two doses of transgenic potatoes (group two) versus those who received three doses of transgenic potatoes (group three) to test the hypothesis that the effect of group one is less than or equal to group two, which is less than or equal to group three. The differences between the three groups were statistically significant when using the Jonckheere–Terpstra test ( 16) ( P < 0.05). The comparisons between groups two (two doses) and three (three doses) revealed no statistically significant differences. |
References 1. Kane, M. (1995) Vaccine 13:, S47-S49. [PubMed]. 2. Coleman, P. J., McQuillan, G. J., Moyer, L. A., Lambert, S. B. & Margois, H. S. (1998) J. Infect. Dis. 178:, 954-959. [PubMed]. 3. McQuillan, G. M., Coleman, P. J., Kruszon-Moran, D., Moyer, L. A., Lambert, S. B. & Margolis, H. S. (1999) Am. J. Public Health 89:, 14-18. [PubMed]. 4. Bloom, B. R. & Widdus, R. (1998) Nat. Med. 4:, Suppl., 480-484. [PubMed]. 5. Haq, T. A., Mason, H. S., Clements, J. D. & Arntzen, C. J. (1995) Science 268:, 714-716. [PubMed]. 6. Mason, H. S., Ball, J. M., Shi, J. J., Jiang, X., Estes, M. K. & Arntzen, C. J. (1996) Proc. Natl. Acad. Sci. USA 93:, 5335-5340. [PubMed]. 7. Mason, H. S., Haq, T. A., Clements, J. D. & Arntzen, C. J. (1998) Vaccine 16:, 1336-1343. [PubMed]. 8. Tacket, C. O., Mason, H. S., Losonsky, G., Clements, J. D., Levine, M. M. & Arntzen, C. J. (1998) Nat. Med. 4:, 607-609. [PubMed]. 9. Tacket, C., Mason, H. S., Losonsky, G., Estes, M. K., Levine, M. M. & Arntzen, C. J. (2000) J. Infect. Dis. 182:, 302-305. [PubMed]. 10. Tacket, C. O., Pasetti, M. F., Edelman, R., Howard, J. A. & Streatfield, S. (2004) Vaccine 22:, 4385-4389. [PubMed]. 11. Thanavala, Y., Yang, Y.-F., Lyons, P., Mason, H. S. & Arntzen, C. J. (1995) Proc. Natl. Acad. Sci. USA 92:, 3358-3361. [PubMed]. 12. Kong, Q., Richter, L., Yang, Y. F., Arntzen, C. J., Mason, H. S. & Thanavala, Y. (2001) Proc. Natl. Acad. Sci. USA 98:, 11539-11544. [PubMed]. 13. Mason, H. S., Lam, D. M. K. & Arntzen, C. J. (1992) Proc. Natl. Acad. Sci. USA 89:, 11745-11749. [PubMed]. 14. Richter, L. J., Thanavala, Y., Arntzen, C. J. & Mason, H. S. (2000) Nat. Biotechnol. 18:, 1167-1171. [PubMed]. 15. Smith, M., Richter, L., Arntzen, C., Shuler, M. & Mason, H. (2003) Vaccine 21:, 4011-4021. [PubMed]. 16. Hollander, M. & Wolfe, D. (1973) in Nonparametric Statistical Methods, eds. Bradley, R. A., Hunter, J. S., Kendall, D. G. & Watson, G. S. (Wiley, New York), pp. 114-137. 17. Argesti, A. (1996) in An Introduction to Categorical Data Analysis, eds. Barnett, V., Bradley, R. A., Fisher, N., Hunter, J. S., Kadane, J. B., Kendall, D. G., Scott, D. W., Smith, A. F. M., Teugels, J. L. & Watson, G. (Wiley, New York), pp. 39-44. 18. Stevens, C. E., Alter, H. J., Taylor, P. E., Zang, E. A., Harley, E. J. & Szmuness, W. (1984) N. Engl. J. Med. 311:, 496-501. [PubMed]. 19. Weber, D. J., Rutala, W. A., Samsa, G. P., Santimaw, J. E. & Lemon, S. M. (1985) J. Am. Med. Assoc. 254:, 3187-3189. 20. Goldwater, P. N. (1997) Vaccine 15:, 353-356. [PubMed]. 21. Jilg, W. (1998) Vaccine 16:, Suppl., S65-S68. [PubMed]. 22. Barash, C., Conn, M .I., DiMarino, A. J., Jr., Marzano, J. & Allen, M. L. (1999) Arch. Intern. Med. 159:, 1481-1483. [PubMed]. 23. Jilg, W., Schmidt, M., Deinhardt, F. & Zachova, R. (1984) Lancet 2: (8400), 458. 24. Tacket, C. O., Losonsky, G., Lubeck, M. D., Davis, A. R., Mizutani, S., Horwith, G., Hung, P., Edelman, R. & Levine, M. M. (1992) Vaccine 10:, 673-676. [PubMed]. 25. Henry, S. H., Bosch, F. X., Troxell., T. C. & Bolger, P. M. (1999) Science 286:, 2453-2454. [PubMed]. 26. Chang, M.-H., Chen, C.-J., Lai, M.-S., Hsu, H.-S., Wu, T.-C., Kong, M.-S., Liang, D.-C., Shau, W.-Y. & Chen, D.-S. (1997) N. Engl. J. Med. 336:, 1855-1859. [PubMed]. |